| Cardiovascular effects of serotonin agonists and antagonists. PR Saxena, CM Villalón Journal of Cardiovascular Pharmacology 15, S17-34, 1990 | 365 | 1990 |
| The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs CM Villalón, J Olesen Pharmacology & therapeutics 124 (3), 309-323, 2009 | 274 | 2009 |
| Calcitonin gene-related peptide and its role in migraine pathophysiology U Arulmani, A MaassenVanDenBrink, CM Villalón, PR Saxena European journal of pharmacology 500 (1-3), 315-330, 2004 | 272 | 2004 |
| 5-hydroxytryptamine and cardiovascular regulation AG Ramage, CM Villalón Trends in pharmacological sciences 29 (9), 472-481, 2008 | 239 | 2008 |
| Cardiovascular responses produced by 5-hydroxytriptamine: a pharmacological update on the receptors/mechanisms involved and therapeutic implications CM Villalón, D Centurión Naunyn-Schmiedeberg's archives of pharmacology 376 (1-2), 45-63, 2007 | 224 | 2007 |
| Wiping out CGRP: potential cardiovascular risks A MaassenVanDenBrink, J Meijer, CM Villalón, MD Ferrari Trends in pharmacological sciences 37 (9), 779-788, 2016 | 222 | 2016 |
| Basic mechanisms of migraine and its acute treatment L Edvinsson, CM Villalón, A MaassenVanDenBrink Pharmacology & therapeutics 136 (3), 319-333, 2012 | 198 | 2012 |
| Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy P De Vries, CM Villalón, PR Saxena European journal of pharmacology 375 (1-3), 61-74, 1999 | 170 | 1999 |
| Potential role of female sex hormones in the pathophysiology of migraine S Gupta, S Mehrotra, CM Villalón, M Perusquía, PR Saxena, ... Pharmacology & therapeutics 113 (2), 321-340, 2007 | 143 | 2007 |
| 5-Hydroxytryptamine: a chameleon in the heart PR Saxena, CM Villalón Trends in pharmacological sciences 12, 223-227, 1991 | 140 | 1991 |
| Cardiovascular alterations after spinal cord injury: an overview G Bravo, G Guizar-Sahagun, A Ibarra, D Centurión, CM Villalón Current Medicinal Chemistry-Cardiovascular & Hematological Agents 2 (2), 133-148, 2004 | 134 | 2004 |
| Gender aspects of CGRP in migraine A Labastida-Ramírez, E Rubio-Beltrán, CM Villalón, ... Cephalalgia 39 (3), 435-444, 2019 | 117 | 2019 |
| Mediation of 5‐hydroxytryptamine‐induced tachycardia in the pig by the putative 5‐HT4 receptor CM Villalón, MO den Boer, JPC Heiligers, PR Saxena British journal of pharmacology 100 (4), 665-667, 1990 | 116 | 1990 |
| 5-HT1-like receptors: a time to bid goodbye PR Saxena, P De Vries, CM Villalon Trends in pharmacological sciences 19 (8), 311-316, 1998 | 110 | 1998 |
| Role of 5‐HT1‐like receptors in the reduction of porcine cranial arteriovenous anastomotic shunting by sumatriptan MO den Boer, CM Villalón, JPC Heiligers, PPA Humphrey, PR Saxena British journal of pharmacology 102 (2), 323-330, 1991 | 108 | 1991 |
| Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy? E Rubio-Beltrán, A Labastida-Ramírez, CM Villalón, ... Pharmacology & therapeutics 186, 88-97, 2018 | 104 | 2018 |
| Side effects associated with current and prospective antimigraine pharmacotherapies A González-Hernández, BA Marichal-Cancino, A MaassenVanDenBrink, ... Expert opinion on drug metabolism & toxicology 14 (1), 25-41, 2018 | 102 | 2018 |
| Pharmacological characterization of VIP and PACAP receptors in the human meningeal and coronary artery KY Chan, M Baun, R Vries, AJ van den Bogaerdt, CMF Dirven, ... Cephalalgia 31 (2), 181-189, 2011 | 91 | 2011 |
| An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy CM Villalón, D Centurión, LF Valdivia, P De Vries, PR Saxena PROCEEDINGS-WESTERN PHARMACOLOGY SOCIETY 45, 199-210, 2002 | 84 | 2002 |
| Experimental migraine models and their relevance in migraine therapy U Arulmani, S Gupta, AM VanDenBrink, D Centurión, CM Villalón, ... Cephalalgia 26 (6), 642-659, 2006 | 81 | 2006 |
